Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Spain biotech ecosystem Sanifit Mallorca

News and Trends 26 Jun 2019

Biotech Company in Mallorca Receives Spain’s Largest Biotech Fundraise

Mallorcan biotech Sanifit has broken the record for the largest private fundraise in the Spanish biotech sector raising a total of €72.2M. The fundraising consists of a €55.2M Series D round plus €17M in convertible bonds. The money will be used by Sanifit to fund an upcoming phase III trial of its lead drug candidate […]

June 26, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

erytech sqz biosciences cell therapy off the shelf

News and Trends 25 Jun 2019

US and French Biotech Partnership to Develop Off-the-Shelf Cell Therapies

The French biotech Erytech will license its red blood cell drug encapsulation technology to the US cell therapy company SQZ Biotechnologies for up to €50M. The partners plan to develop off-the-shelf cell therapies combining Erytech’s red blood cell drug encapsulation with SQZ Biotechnologies’ technology, which engineers immune cells to attack or protect specific disease targets. […]

June 25, 2019 - 2 minutesmins - By Jonathan Smith

nash liver fibrosis genfit terns pharmaceuticals organ

News and Trends 25 Jun 2019

Genfit’s NASH Drug to Be Developed in China in Deal Worth up to €200M

The US-Chinese company Terns Pharmaceuticals will develop and commercialize Genfit’s phase III drug elafibranor for the chronic liver disease NASH in China. As part of the deal, Genfit will receive a €31M ($35M) upfront fee and up to €170M ($193M) in developmental milestone payments. The two companies will also collaborate on other development programs for […]

June 25, 2019 - 3 minutesmins - By Jonathan Smith

Vesalius Biocapital late stage fund

News and Trends 25 Jun 2019

Update: Fund for Late-Stage European Biotechs Closes Final Round With €120M

Update (25/06/2019): The Luxembourg-based investor Vesalius Biocapital III has completed the final closing of a €120M fund to boost late-stage life science companies. Around 10-15 companies will receive investments from the fund, including specialists in drug development, med-tech, and diagnostics. Three companies have become beneficiaries so far, including the Finnish women’s health drug company Forendo […]

June 25, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

heart disease cardiovascular disease cholesterol zora biosciences

News and Trends 24 Jun 2019

Diagnostic Test Beats ‘Bad’ Cholesterol at Predicting Heart Attacks

A study run by the Finnish diagnostics biotech Zora Biosciences has found two biomarkers that are better at predicting heart attacks and deaths in patients with coronary heart disease than the current gold standard — measuring ‘bad’ cholesterol in the blood. To assess the risk of death or heart attacks in people with coronary […]

June 24, 2019 - 2 minutesmins - By Jonathan Smith

fecal transplant maat pharma fda enterobiotix

News and Trends 21 Jun 2019

Will US Fecal Transplant Death Impact European Biotech?

The death of a US patient from complications after a fecal transplant last week could have a major impact on microbiome research in Europe. The microbiome is a field with big potential for treating disease by targeting imbalances in the patient’s gut flora, such as by giving patients the stool bacteria of a healthy person […]

June 21, 2019 - 2 minutesmins - By Jonathan Smith

ADVERTISEMENT

atelerix cell therapy newcastle freeze encapsulation

News and Trends 21 Jun 2019

This Biotech Transports Cell Therapies Without Needing a Freezer

The biotech Atelerix, based in Newcastle, UK, can transport cell therapies between different locations with less cost and risk than current methods by encapsulating the cells in a specialized gel. Mission: To eliminate the need for costly cold storage in the cell transport process by preserving cells in a gel. This could save further costs […]

June 21, 2019 - 3 minutesmins - By Jonathan Smith

organoid spider silk biolamina

News and Trends 20 Jun 2019

Spider Silk Could Improve Organoids for Drug Development

The Stockholm-based organoids company BioLamina has teamed up with the recombinant spider silk Stockholm startup Spiber Technologies to develop organoids that are more accurate tissue models than those used currently. Organoids are gaining popularity as a drug testing tool due to their capacity for modeling human tissue in 3D, which is more representative than 2D […]

June 20, 2019 - 2 minutesmins - By Jonathan Smith

head and neck cancer organoids hubrecht

News and Trends 19 Jun 2019

Scientists Grow Head and Neck Cancer Organoids to Personalize Chemotherapy

A team of Dutch researchers has developed the first 3D organoids from patients’ head and neck cancer cells that can be kept alive for a long time, giving physicians a model to test which cancer treatments are the most effective for each patient. Head and neck cancer is an aggressive disease that often requires harsh […]

June 19, 2019 - 3 minutesmins - By Jonathan Smith

ovarian cancer astrazeneca merck lynparza dna repair

News and Trends 19 Jun 2019

EU Gives Lynparza Green Light as First-Line Ovarian Cancer Treatment

The DNA damage repair drug olaparib (Lynparza), developed by AstraZeneca and Merck, has been approved by the EU as a first-line treatment preventing the return of ovarian cancer after initial chemotherapy. The drug has already been approved by the EU and the FDA as a maintenance treatment for relapsed ovarian cancer, and as a therapy […]

June 19, 2019 - 3 minutesmins - By Jonathan Smith

Industrial biotechnology companies Europe

Best in Biotech 19 Jun 2019

The Top 20 Industrial Biotechnology Companies in Europe

Europe’s industrial biotechnology sector is driving a massive change from petrochemical processes to more sustainable alternatives. Here are the top industrial biotechnology companies in Europe making every industry greener. Industrial biotechnology draws from biology and the billions of years of evolution behind it to make the production of any chemical compound more efficient and more […]

June 19, 2019 - 8 minutesmins - By Clara Rodríguez Fernández

type 1 diabetes imcyse immunotherapy

News and Trends 18 Jun 2019

Belgian Biotech’s €35M Series B to Fund Potential Type 1 Diabetes Cure

The Belgian company Imcyse has raised €35M in a Series B round to develop a potential cure for chronic autoimmune conditions including type 1 diabetes and multiple sclerosis. Imcyse will use the money to fund phase II trials of a peptide-based treatment for type 1 diabetes. The funds will also help the company to launch […]

June 18, 2019 - 2 minutesmins - By Jonathan Smith

ADVERTISEMENT